Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Eitemau Tebyg

• Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
  gan: Ahn, Myung-Ju, et al.
  Cyhoeddwyd: (2015)
• Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
  gan: Kim, Youjin, et al.
  Cyhoeddwyd: (2019)
• An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
  gan: Park, Keunchil, et al.
  Cyhoeddwyd: (2021)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
  gan: Jung, Hyun Ae, et al.
  Cyhoeddwyd: (2020)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
  gan: Hyun Ae Jung, et al.
  Cyhoeddwyd: (2020-10-01)